5th Annual Princess Margaret Lung Oncology Research Day

This annual event celebrates our achievements in clinical and translational research and is an opportunity to promote interdepartmental collaborations amount researchers. The purpose of this conference is for the lung group to share, update, and discuss ongoing lung cancer research across the entire multi-disciplinary spectrum with participation from researchers, clinicians, and trainees.

Trainees (i.e., clinical fellows, postdoctoral fellows,& residents) currently working under the supervision of a Principal Investigator at the lung site are invited to submit an abstract for an oral presentation.

Abstracts submitted to international or national meetings over the past year are welcome. There will be Awards for the best clinical and basic science presentations.

Registration is free and we encourage everyone to register as soon as possible.

If you plan to submit an abstract, please register and then email your abstract to lungoncologygroup@uhn.ca

Please mark your calendars for October 25, 2024 and we look forward to seeing you there!

IMPORTANT DATES:
Abstract Submission Deadline: Thursday, October 10, 2024 at 4:00 p.m. (no late submissions will be accepted)
Registration Closes: Sunday, October 20, 2024 at 4:00 pm.

Online registration is mandatory for all presenters and general attendees.

GUEST SPEAKER

Dr. Ignacio I. Wistuba, MD

Professor and Chair, Department of Translational Molecular Pathology, Division of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Dr. Ignacio Wistuba is the Chair of the Department of Translational Molecular Pathology and Professor of the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.

Dr. Wistuba’s research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer. Dr. Wistuba's work includes the identification of new molecular targets, validation of biomarkers for targeted therapy, and identification of molecular markers associated with metastasis development.

Dr. Pamela Ohashi, PhD, FRSC

Dr. Pamela Ohashi is a Senior Scientist, Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, and Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. Dr. Ohashi holds the Canada Research Chair in Autoimmunity and Tumour Immunity.

Dr. Ohashi is focused on understanding the mechanisms that determine whether T cells are activated or tolerized in vivo. Dr. Ohashi’s lab employed transgenic and gene knock out mouse models to evaluate the molecular pathways that govern T cell fate. Dr. Ohasi’s research interests include T cell responses to tissues, with a goal to understand and control autoimmune and anti-tumor immune responses.

Dr. Daniel De Carvalho, PhD

Dr. Daniel De Carvalho is a Senior Scientist at the Princess Margaret Cancer Centre. Dr. De Carvalho's research focuses on basic and translational aspects of cancer epigenetics. His lab is developing DNA methylation-based liquid biopsy tools combined with advanced computational approaches applied to cancer early detection, classification and monitoring.

Patrick Veit-Haibach, MD

Dr. Patrick Veit-Haibach is a dual-certified Radiologist and Nuclear Medicine Physician. His research interests focus on multi-modality molecular imaging strategies, particularly combined PET/MRI and PET/CT, perfusion- and hypoxia-imaging. Current projects involve clinical and preclinical molecular imaging research in esophago-gastric cancer, hematological and lymphomatous malignancies, breast cancer, HCC, sarcoma and ENT cancer as well as hybrid-modality hypoxia imaging and machine learning endeavors in PET.